Aristides Capital’s Niagen Bioscience NAGE Stock Holding History

Aristides Capital’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24,278	Closed	-$91K	–	303
2021 Q4	$91K	Buy	+24,278	New	+$131K	0.04%	246

Other funds holding NAGE

YRHAM

Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aristides Capital's NAGE Position: Q1 2022 in Review

Aristides Capital sold out of Niagen Bioscience (NAGE) in Q1 2022, closing a stake of 24,278 shares — an estimated $91K sold.

Aristides Capital first reported a position in NAGE in Q4 2021 and held it in 1 quarter. The position peaked at $91K in Q4 2021. 82 funds tracked by Wall St. Rank hold NAGE as of Q1 2022.

Aristides Capital reported no remaining Niagen Bioscience position as of Q1 2022 after selling out during the quarter.
Aristides Capital sold 24,278 Niagen Bioscience shares in Q1 2022, an estimated $91K.
Aristides Capital first reported a position in Niagen Bioscience in Q4 2021 and held it in 1 quarter.
Aristides Capital's Niagen Bioscience position peaked at $91K in Q4 2021.
82 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.